Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Achieve Life Sciences, Inc. ACHV NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • CA • USD

SharesGrow Score
48/100
2/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$4.75
+31.6%

Achieve Life Sciences, Inc. (ACHV) is a Biotechnology company in the Healthcare sector, currently trading at $3.61. It has a SharesGrow Score of 47/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is ACHV = $5 (+31.6% upside).

Valuation: ACHV trades at a trailing Price-to-Earnings (P/E) of -3.2 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.12.

Net income is $55M (loss), growing at -14%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $15M against $22M equity (Debt-to-Equity (D/E) ratio 0.69, moderate). Current ratio is 4.39 (strong liquidity). Debt-to-assets is 35.8%. Total assets: $42M.

Analyst outlook: 6 / 6 analysts rate ACHV as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 96/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 50/100 (Partial), Moat 28/100 (Fail), Future 100/100 (Pass), Income ?/100 (Fail).

$4.75
▲ 31.58% Upside
Average Price Target
Based on 6 Wall Street analysts offering 12-month price targets for Achieve Life Sciences, Inc., the average price target is $4.75, with a high forecast of $5.50, and a low forecast of $4.00.
Highest Price Target
$5.50
Average Price Target
$4.75
Lowest Price Target
$4.00

ACHV SharesGrow Score Overview

58/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 96/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 50/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ACHV

✓
VALUE Pass
96/100
ACHV trades at a trailing Price-to-Earnings (P/E) of -3.2 (S&P 500 average ~25). Forward PEG 0.12 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $5, implying +38.5% from the current price $4. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
ACHV: +0%/yr revenue is, -14%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
50/100
Balance sheet ACHV: Debt-to-Equity (D/E) ratio 0.69 (moderate), Current ratio is 4.39 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
ACHV: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 6 / 6 analysts rate ACHV as buy (100%). Analyst consensus target is $5 (+38.5% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range1.84-6.03
Volume504.21K
Avg Volume (30D)654.95K
Market Cap$192.2M
Beta (1Y)1.96
Share Statistics
EPS (TTM)-1.25
Shares Outstanding$43.59M
IPO Date1995-10-12
Employees25
CEORichard A. Stewart
Financial Highlights & Ratios
Gross Profit$-228K
EBITDA$-54.65M
Net Income$-54.65M
Operating Income$-54.88M
Total Cash$36.4M
Total Debt$14.96M
Net Debt$-5.97M
Total Assets$41.79M
Price / Earnings (P/E)-2.9
Analyst Forecast
1Y Price Target$4.75
Target High$5.50
Target Low$4.00
Upside+31.6%
Rating ConsensusBuy
Analysts Covering6
Buy 100% Hold 0% Sell 0%
Price Target Summary
Company Info
CountryCA
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS0044685008

Price Chart

Track all markets on TradingView
ACHV
Achieve Life Sciences, Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
1.84 52WK RANGE 6.03

People Also View

APLS
APLS
Apellis Pharmaceuticals, Inc.
$40.85
+0.02%
 DAWN
DAWN
Day One Biopharmaceuticals, Inc.
$21.46
-0.14%
 VECT
VECT
VectivBio Holding AG
$16.87
+0.12%
 CTMX
CTMX
CytomX Therapeutics, Inc.
$4.54
+3.42%
 ICVX
ICVX
Icosavax, Inc.
$15.31
-0.91%
 IMMX
IMMX
Immix Biopharma, Inc.
$9.85
+1.65%
 ASMB
ASMB
Assembly Biosciences, Inc.
$29.44
+0.68%
 ITOS
ITOS
iTeos Therapeutics, Inc.
$10.15
+0.20%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message